Targeting adipose tissue in the treatment of obesity-associated diabetes

被引：557
作者：
Kusminski, Christine M. [1 ]
Bickel, Perry E. [2 ]
Scherer, Philipp E. [1 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Touchstone Diabet Ctr, Dallas, TX 75390 USA
[2] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Div Endocrinol, Dallas, TX 75390 USA
来源：
NATURE REVIEWS DRUG DISCOVERY | 2016年 / 15卷 / 09期
基金：
美国国家卫生研究院;
关键词：
BONE MORPHOGENETIC PROTEIN-7; ACTIVATED-RECEPTOR-GAMMA; MESENCHYMAL STEM-CELLS; IMPROVES INSULIN-RESISTANCE; PLACEBO-CONTROLLED TRIAL; LIFE-STYLE INTERVENTION; NECROSIS-FACTOR-ALPHA; FATTY LIVER-DISEASE; FACTOR; 21; FGF21; PPAR-GAMMA;
D O I：
10.1038/nrd.2016.75
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Adipose tissue regulates numerous physiological processes, and its dysfunction in obese humans is associated with disrupted metabolic homeostasis, insulin resistance and type 2 diabetes mellitus (T2DM). Although several US-approved treatments for obesity and T2DM exist, these are limited by adverse effects and a lack of effective long-term glucose control. In this Review, we provide an overview of the role of adipose tissue in metabolic homeostasis and assess emerging novel therapeutic strategies targeting adipose tissue, including adipokine-based strategies, promotion of white adipose tissue beiging as well as reduction of inflammation and fibrosis.
引用
收藏
页码：639 / U84
页数：22
相关论文
共 300 条
[1]   The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue [J].
Adams, Andrew C. ;
Yang, Chaofeng ;
Coskun, Tamer ;
Cheng, Christine C. ;
Gimeno, Ruth E. ;
Luo, Yongde ;
Kharitonenkov, Alexei .
MOLECULAR METABOLISM, 2013, 2 (01) :31-37
[2]   LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys [J].
Adams, Andrew C. ;
Halstead, Carolyn A. ;
Hansen, Barbara C. ;
Irizarry, Armando R. ;
Martin, Jennifer A. ;
Myers, Sharon R. ;
Reynolds, Vincent L. ;
Smith, Holly W. ;
Wroblewski, Victor J. ;
Kharitonenkov, Alexei .
PLOS ONE, 2013, 8 (06)
[3]   Leptin regulation of neuroendocrine systems [J].
Ahima, RS ;
Saper, CB ;
Flier, JS ;
Elmquist, JK .
FRONTIERS IN NEUROENDOCRINOLOGY, 2000, 21 (03) :263-307
[4]   Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy [J].
Akinci, Gulcin ;
Akinci, Baris .
RECENT PATENTS ON ENDOCRINE METABOLIC & IMMUNE DRUG DISCOVERY, 2015, 9 (02) :74-78
[5]   Irisin - a myth rather than an exercise-inducible myokine [J].
Albrecht, Elke ;
Norheim, Frode ;
Thiede, Bernd ;
Holen, Torgeir ;
Ohashi, Tomoo ;
Schering, Lisa ;
Lee, Sindre ;
Brenmoehl, Julia ;
Thomas, Selina ;
Drevon, Christian A. ;
Erickson, Harold P. ;
Maak, Steffen .
SCIENTIFIC REPORTS, 2015, 5
[6]   PPAR gamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A [J].
Altiok, S ;
Xu, M ;
Spiegelman, BM .
GENES & DEVELOPMENT, 1997, 11 (15) :1987-1998
[7]   6. Obesity Management for the Treatment of Type 2 Diabetes [J].
不详 .
DIABETES CARE, 2016, 39 :S47-S51
[8]   Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture [J].
Amit, M ;
Carpenter, MK ;
Inokuma, MS ;
Chiu, CP ;
Harris, CP ;
Waknitz, MA ;
Itskovitz-Eldor, J ;
Thomson, JA .
DEVELOPMENTAL BIOLOGY, 2000, 227 (02) :271-278
[9]   Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis [J].
Amori, Renee E. ;
Lau, Joseph ;
Pittas, Anastassios G. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (02) :194-206
[10]  
Anderson K, 2014, AM HEALTH DRUG BENEF, V7, P231
12345678910